clinical trial · NCT02780128
Next Generation Personalized Neuroblastoma Therapy
Yael P Mosse·phase1·terminated·n = 66
NeuroblastomaCancerBiopsyNext Generation SequencingTumor ScansBone marrow TestsPhysical ExamEye ExamLabsPregnancy Test
brief summary
The purpose of this research study is to match genomic aberrations in tumor cells at time of relapse to rationally designed combinations of molecularly targeted agents. This study will be done in two parts: Part I: Tumor will be accessed at study entry via a biopsy and subjected to deep sequencing to identify protocol-specified biomarkers for therapy assignment. Part II: If the tumor contains a genetic change defined by the study as being actionable, and other criteria are met, participants will be assigned to therapy based upon the genetic changes identified in the tumor biopsy.
started
Jul 1, 2016
primary completion
Aug 1, 2022
completion
Aug 1, 2022
last updated
Mar 10, 2026
official title
Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol